In what can only be described as a dramatic setback for the company, GI Dynamics (Lexington, Massachusetts/ Sydney, Australia) is reporting that the FDA has placed a hold on enrollment in the firm's ongoing pivotal clinical trial of EndoBarrier Therapy. The hold comes after there were four cases of a bacterial infection of the liver or hepatic abscess reported in the ENDO Trial. Upon the news, stock from the company plummeted. Read More
